SL Science Holding Ltd（SLBT）股价、财务与研究

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

2026年7月10日

22/ 100

GoAI 评分

卖出

估值

10

估值过高

情绪

50

多空交织

风险

63

高风险

动量

17

强势下行

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

公司概况

公司网站

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: William Wang
上市以来: 2025年2月5日
雇员: 15

市场位置

日内区间

当前US$1.51

US$1.47US$1.53

52周区间

当前US$1.51

US$1.42US$14.50

开盘价: US$1.47
前收盘价: US$1.51
成交量: 2.34万; 0.04× 平均值
平均成交量: 58.5万; 日均成交量
市值: 8.47亿 USD
贝塔: 0.09; 市场参考 1
50天平均值: US$2.2904; 低于平均水平-34.07%
200天平均值: US$6.734; 低于平均水平-77.58%

财务数据

财务快照

估值与收益率

企业价值: -104.52万 USD
市盈率（TTM）: 0×
市净率（TTM）: 0×
市销率（TTM）: 385.37×
EV/EBITDA: 0.28×
盈利收益率: 0.00%
自由现金流收益率: 0.00%
股息率: 0.00%

盈利能力和效率

毛利率: 35.27%
营业利润率: -174.65%
净利润率: -173.85%
净资产收益率: -167.25%
资产收益率: -135.59%
投入资本回报率: -153.66%

财务健康

负债权益比: 0.09×
流动比率: 3.05×

财务报表

利润率趋势

盈利能力占已公布营收的百分比。

毛利率营业利润率净利润率

损益趋势

营收

219.72万 USD-34.68%

营业利润

−383.75万 USD-220.83%

净利润

−381.98万 USD-220.63%

财务报表: 损益表
项目（USD）	2025财年	2024财年	2023财年
营收	219.72万 USD	336.36万 USD	87.9万 USD
销货成本	142.22万 USD	143.08万 USD	14.1万 USD
毛利	77.51万 USD	193.28万 USD	73.8万 USD
研究与开发	206.9万 USD	202.03万 USD	—
销售、一般及管理费用	254.35万 USD	110.85万 USD	64.12万 USD
营业费用	461.26万 USD	312.89万 USD	64.12万 USD
利息收入	4.03万 USD	4.53万 USD	1612 USD
折旧和摊销	9.37万 USD	4.72万 USD	3.72万 USD
营业利润	−383.75万 USD	−119.61万 USD	9.68万 USD
净利润	−381.98万 USD	−119.13万 USD	39.9万 USD

公司数据更新于 2026年10月13日。

财报历史与展望

最新财年每股收益: 0; 2025财年
最新财年收入: 219.72万 USD; 2025财年 · 同比-34.68%

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期

SLBT 消息

globenewswire.com2026年9月24日

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy's ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.

阅读源码

seekingalpha.com2026年9月16日

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered…

阅读源码

globenewswire.com2026年9月2日

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene…

阅读源码

globenewswire.com2026年8月27日

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene…

阅读源码

globenewswire.com2026年8月11日

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and…

阅读源码

globenewswire.com2026年7月17日

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

阅读源码

SLBT同业公司

AMGN

Amgen Inc.

US$417.57

+0.65%

GILD

Gilead Sciences, Inc.

US$150.43

-0.49%

ISRG

Intuitive Surgical, Inc.

US$427.64

+0.87%

VRTX

Vertex Pharmaceuticals Incorporated

US$507

-0.60%

SNY

Sanofi

US$39.74

-0.82%

MRNA

Moderna, Inc.

US$213.74

-5.00%

SL Science Holding Ltd

SLBT公司概览

公司概况

SL Science Holding Ltd

SLBT公司概览

GoAI 研究快照

公司概况

市场位置

财务数据

财务快照

估值与收益率

盈利能力和效率

财务健康

财务报表

利润率趋势

损益趋势

财报历史与展望

年度每股收益趋势

年度营收趋势

SLBT 消息

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SLBT同业公司

继续GoAI的研究

SLBT公司概览

公司概况

市场位置

SLBT公司概览

公司概况

SLBT公司概览

公司概况

市场位置

SLBT公司概览

GoAI 研究快照

公司概况

市场位置

财务数据

财务快照

估值与收益率

盈利能力和效率

财务健康

财务报表

利润率趋势

损益趋势

财报历史与展望

年度每股收益趋势

年度营收趋势

SLBT 消息

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SLBT同业公司

继续GoAI的研究